Straits Times Index
3,290.70 +24.75 (+0.76%) Nikkei
38,229.11 +155.13 (+0.41%) Hang Seng
18,963.68 +425.87 (+2.30%) FTSE 100
8,433.76 +52.41 (+0.63%) Bitcoin USD
61,093.04 +368.43 (+0.61%) CMC Crypto 200
1,264.78 -93.23 (-6.87%)
Fortress Biotech, Inc. (FBIOP)
| Previous close | 16.37 |
| Open | 16.27 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 15.98 - 16.48 |
| 52-week range | 6.40 - 18.73 |
| Volume | |
| Avg. volume | 11,317 |
| Market cap | 85.779M |
| Beta (5Y monthly) | 1.55 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 2.34 (14.67%) |
| Ex-dividend date | 12 Apr 2024 |
| 1y target est | N/A |
- GlobeNewswire
Checkpoint Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Updates
WALTHAM, Mass., May 10, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the first quarter ended March 31, 2024, and recent corporate updates. James F. Oliviero, President and Chief Executive Officer of Checkpoint, said, “Over the past few months, we have worked closely with our third-party contract manufacturing organization (“CMO”) for cosibelimab to resolve
- GlobeNewswire
Journey Medical Corporation to Announce First Quarter 2024 Financial Results on May 13, 2024
Company to host conference call to discuss financial results and provide a corporate update on May 13, 2024 at 4:30 p.m. ETSCOTTSDALE, Ariz., May 07, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that focuses on the selling and marketing of FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the Company will release its first quarter
- GlobeNewswire
Mustang Bio Announces Closing of $4 Million Public Offering
Potential Additional Gross Proceeds Upon Cash Exercise of Warrants of Up to $12 MillionWORCESTER, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers, today announced the closing of its previously announced public offering for the purchase and sale of an aggregate of 16,877
